Serina Therapeutics
Huntsville
About Serina Therapeutics
Serina Therapeutics is a privately-held pharmaceutical company that is advancing novel therapeutics for cancer, inflammation, pain, and metabolic disorders using its proprietary polymer technology. They have created new pharmaceutical candidates using polyoxazoline (POZ), a safe, water-soluble polymer to which they can attach a variety of small molecules, proteins, peptides, and DNA. The attachment of these molecules to polymers of POZ typically confers a unique pharmacokinetic profile that is markedly different from the parent compound, and this profile may confer advantages in terms of safety and efficacy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $65.7M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: nysemkt:SER
- Website: serinatherapeutics.com
- Phone: 256-327-0566
Industries & Categories
Biopharma, Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/serina-therapeutics-14491 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.